Glyko gets grant for lysosomal storage diseases tests:
This article was originally published in Clinica
Glyko Biomedical has been awarded a Phase II small business innovative research grant to develop a second-generation diagnostic test system for the group of inherited metabolic disorders called lysosomal storage diseases. The grant, from the National Institute of Child Health and Human Development, is just under $600,000 over two years. Glyko, based in Novato, California, estimates there are more than 35 lysosomal storage diseases, which affect over 30,000 people in the US.
You may also be interested in...
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.